


MAY 12 2003

PTO/SB/10-00  
Approved for use through 10/31/2002. OMB 0651-0035  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it display a valid OMB control number.

#10/Revoc  
D.O.A.



## REVOCATION AND SUBSTITUTE POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

Application Number	See Attached Appendix A
Filing Date	See Attached Appendix A
First Named Inventor	See Attached Appendix A
Group Art Unit	Not yet known
Examiner Name	Not yet known
Attorney Docket Number	See Attached Appendix A

I hereby revoke all previous powers of attorney or authorizations of agent given in the above-identified application, and I hereby appoint:



Practitioner(s) named below:

Herb Boswell, Reg. No. 27,311; Laurel S. Bernstein, Reg. No. 37,280; Robert S. Andrews, Reg. No. 44,508; Neil Bartfeld Reg. No. 39,901; Matthew Grumbling, Reg. No. 44, 427; Donna T. Ward, Reg. No. 48,271; Kenneth Tarbet, Reg. No. 43,181; Laura Handley, Reg. No. 39,704; Michael Shuster, Reg. No. 41,310; Susan T. Hubl, Reg. No. 47,668.

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address to, and associate the above-identified application with:

0035807



Practitioners at Customer Number

OR

RECEIVED

<input type="checkbox"/> Firm or Individual Name			
Address	MAY 14 2003		
Address			
City	State	Zip	
Country			
Telephone	Fax		

I am the:



Applicant/Inventor.



Assignee of record of 100% interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

MAY 14 2003


TECH CENTER 1600/2900

### SIGNATURE of Applicant or Assignee of Record

Name	B. Lynne Parshall
Title	Executive Vice President
Signature	
Date	4/21/03

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below\*.

\*Total of 1 forms are submitted.

**Certificate Under 37 CFR § 3.73(b)****RECEIVED**

Applicant:  
Application No.:  
Filing Date:

See Attached Appendix A

MAY 14 2003

Name of Assignee:

See Attached Appendix A

Type of Assignee (e.g. corporation, partnership, university, government agency, etc.):

Isis Pharmaceuticals, Inc.

TECH CENTER 1600/2900

Corporation

The above-mentioned Assignee certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of either:

A.  An assignment from the inventor(s) of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel       , Frame       . See attached Appendix A for information. OR

B.  A chain of title from the inventor(s), of the patent application identified above, to the current assignee as shown below:

1. From: \_\_\_\_\_  
To: \_\_\_\_\_  
The document was recorded in the Patent and Trademark Office at  
Reel: \_\_\_\_\_ and Frame: \_\_\_\_\_, or for which a copy thereof is attached.
2. From: \_\_\_\_\_  
To: \_\_\_\_\_  
The document was recorded in the Patent and Trademark Office at  
Reel: \_\_\_\_\_ and Frame: \_\_\_\_\_, or for which a copy thereof is attached.
3. From: \_\_\_\_\_  
To: \_\_\_\_\_  
The document was recorded in the Patent and Trademark Office at  
Reel: \_\_\_\_\_ and Frame: \_\_\_\_\_, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned (whose title is supplied below) is empowered to sign this certificate on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

4/21/03

Date

Signature

B. Lynne Parshall

Name

Executive Vice President and CFO

Title



**APPENDIX A**  
**Assignee: ISIS PHARMACEUTICALS, INC.**



**Assignee: ISIS PHARMACEUTICALS INC**



**APPENDIX A**  
**Assignee: ISIS PHARMACEUTICALS, INC.**

Assignee: ISIS PHARMACEUTICALS, INC.



**APPENDIX A**  
**Assignee: ISIS PHARMACEUTICALS, INC.**

ISIS No.	Atty Docket No.	Application No.	Assignors	Group Art	Reel	Frame	Recorded
				Unit			
RTS-0369	23546-07713	10/174,020 06/17/2002	Brett P. Monia Kenneth W. Dobie	1646	013023	0086	06/17/02
		<b>Title: Antisense Modulation of Hypothetical Tumor Endothelial Marker Expression</b>					
RTS-0374	23546-07714	10/174,456 07/17/2002	Brett P. Monia Susan M. Freier	1642	013034	0593	06/17/02
		<b>Title: Antisense Modulation of G Protein-Coupled Receptor 49 Expression</b>					
RTS-0375	23546-07715	10/100,100 07/18/2002	Lex M. Cowser Kenneth W. Dobie	1645	013131	0001	07/18/02
		<b>Title: Antisense Modulation of LAM Domain Kinase 1 Expression</b>					
RTS-0377	23546-07716	10/185,035 06/28/2002	Brett P. Monia Kenneth W. Dobie	1635	013076	0088	06/28/02
		<b>Title: Antisense Modulation of DEXRAS1 Expression</b>					
RTS-0379	23546-07717	10/187,659 07/01/2002	Kenneth W. Dobie	1642	013087	0188	07/01/02
		<b>Title: Antisense Modulation of P2X4 Expression</b>					
RTS-0333	23546-07724	10/008/789 11/08/2001	C. Frank Bennett Kenneth W. Dobie	1635	021370	0920	11/08/01
		<b>Title: Antisense Modulation of Thyroid Hormone Receptor Interactor 6 Expression</b>					
HTS-0026	23546-07755	10/293,998 11/11/2002	Ming-Yi Chuang Kenneth W. Dobie	1653	013504	0558	11/11/02
		<b>Title: Modulation of B Protein-Coupled Receptor Re2 Expression</b>					

Revised: May 8, 2003